Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Treatment of prostatic carcinoma with UFT and leucovorin--basic study using SRCA]

K Uchida1, T Hayashi, T Shiga

  • 1Dept. of Urology, University of Tsukuba.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1994
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction.

Urologic oncology·2011
Same author

New treatment approaches for superficial and invasive bladder cancer.

Urologic oncology·2011
Same author

Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers.

Prostate cancer and prostatic diseases·2009

The combination of UFT and leucovorin significantly enhanced anticancer effects against rat prostatic carcinoma. This suggests UFT with leucovorin may be clinically useful for advanced, hormonally refractory prostate cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Context:

  • Prostate cancer remains a significant health concern, particularly in its advanced and hormonally refractory stages.
  • Current treatment options for advanced prostate cancer have limitations, necessitating the exploration of novel therapeutic strategies.
  • The UFT (uracil and tegafur) and leucovorin combination has shown preclinical promise in other cancer types.

Purpose:

  • To evaluate the combined anticancer efficacy of UFT and leucovorin against a specific rat prostatic carcinoma model (R-3327).
  • To determine if leucovorin administration potentiates the antitumor activity of UFT in this model.
  • To assess the potential clinical utility of this drug combination for patients with advanced, hormone-refractory prostate cancer.

Summary:

Related Experiment Videos

  • The subrenal capsular assay (SRCA) in nude mice was employed to assess the combination effect of UFT and leucovorin on rat prostatic carcinoma (R-3327).
  • Co-administration of both low and high doses of leucovorin significantly augmented the anticancer effect of UFT.
  • The observed synergistic effect indicates enhanced tumor inhibition when UFT is combined with leucovorin.

Impact:

  • These findings suggest a potential clinical benefit of using UFT in combination with leucovorin for patients suffering from hormonally refractory advanced prostate cancer.
  • This research may pave the way for new treatment regimens in difficult-to-treat prostate cancer cases.
  • The study provides a strong rationale for further clinical investigation into UFT-leucovorin therapy for advanced prostate cancer.